The role of capmatinib (Tourad) in the treatment of lung cancer and recommendations for users

Capmatinib (trade name Tabrecta) is an oral small molecule METTyrosine kinase inhibitor, mainly targeting METexon14skipping mutation (METTyrosine kinase inhibitor pan>METex14) and some MET gene amplified non-small cell lung cancer (NSCLC) patients. By inhibiting the MET signaling pathway, capmatinib can block tumor cell proliferation, migration and angiogenesis, thereby delaying tumor progression and improving patients' motor function and quality of life.

Clinical studies have shown that capmatinib has a significant effect on METex14 mutated NSCLC patients. GEOMETRY The results of the mono-1 study show that the objective response rate (ORR) of patients without chemotherapy can reach 68%, and that of patients who have previously received chemotherapyORR is about 41%, and the median progression-free survival (PFS) is between 7 and 12 months. The efficacy is mainly reflected in extending the "disease control time" and improving symptoms, including cough, dyspnea and fatigue.

Capmatinib is mainly suitable for patients with advanced or metastatic NSCLC confirmed by molecular testing METex14 mutation or MET high-level amplification. For newly treated patients who have not received chemotherapy, capmatinib can be used as a first-line treatment option; for patients who have failed previous chemotherapy, it can also be used as a second-line or subsequent treatment option. The patient's liver function, renal function and cardiovascular condition should be assessed before use to ensure medication safety.

In clinical practice, patients need to regularly review hematological indicators, liver function and blood pressure while taking capmatinib. Common adverse reactions include edema, nausea, vomiting and thrombocytopenia. The doctor can adjust the dose or suspend the medication based on tolerance. Overall, capmatinib provides a new option for precise targeted therapy for patients with MET-driven NSCLC, helping to extend survival and improve quality of life.

Reference link:https://www.drugs.com